Meningeal gliomatosis--clinical features and results of treatment
Arita, N.; Hayakawa, T.; Mogami, H.; Ushio, Y.
Gan no Rinsho. Japan Journal of Cancer Clinics 35(11): 1308-1312
1989
ISSN/ISBN: 0021-4949 PMID: 2478733 Document Number: 340760
Fifteen (15.6%) patients of 97 with malignant glioma developed meningeal gliomatosis during at least 2 years after the initial treatment. The time between the first surgery and diagnosis of meningeal gliomatosis was less than 1 year in 10 cases, 1 to 2 years in 2 and over 2 years in 2. In the younger age group less than 20 years, the incidence of meningeal gliomatosis was higher (46%) than that (12%) in the older group. Despite intrathecal chemotherapy (cytosine arabinoside, bleomycin and methotrexate), all patients died 2 to 24 weeks after the diagnosis of meningeal gliomatosis. Experimental studies suggest that intrathecal ACNU may be promising for the treatment of meningeal gliomatosis.